1256288-29-5

Upstream product

• 1403265-58-6 C₂₁H₃₄NO₇P 
• 100-39-0 benzyl bromide 
• 1199613-03-0 (2S,3R)-4-[di-(tert-butyl-oxy)-phosphinyl]-N-(phenylmethoxycarbonyl)-L-valine methyl ester 
• 1256287-06-5 C₂₀H₃₀BrNO₄Si 
• 13086-84-5 di-tert-butyl phosphite 
• 1256287-05-4 (4R)-3-[(2S,3R)-2-azido-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-methyl-1-oxo-butyl]-4-phenyl-2-oxazolidinone 
• 178755-10-7 dimethyl (2S,3R)-N-benzyl-3-methyl-N-(9-phenylfluoren-9-yl)aspartate 

Downstream Products

• 1454788-48-7 ((((2R,3S)-4-(benzyloxy)-3-(((benzyloxy)carbonyl)amino)-2-methyl-4-oxobutyl)phosphoryl)bis(oxy))bis(methylene)bis(2,2-dimethylpropanoate) 

Relevant academic research and scientific papers

Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds.

Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form

Reported herein are the synthesis and solid-phase peptide incorporation of N-Fmoc-(2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid bis-pivaloyloxymethyl phosphoryl ester [Fmoc-Pmab(POM)2-OH, 2] as a phosphatase-stable phosphothreonine (pThr) mimetic bearing orthogonal protection suitable for the synthesis of Pmab-containing peptides having bio-reversible protection of the phosphonic acid moiety. This represents the first report of a bio-reversibly protected pThr mimetic in a form suitable for facile solid-phase peptide synthesis.